Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2023-04-17 Major Shareholding Noti…
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., open market purchases, stock option exercises), and the purpose of holding (influence on management). This fits the definition of a 'Major Shareholding Notification' (MRQ).
2023-04-17 Korean
투자판단관련주요경영사항(혈우병 우회인자 TU7710 의 한국 MFDS 임상 1a상 시험계획 (IND) 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) announcing the approval of a clinical trial (IND) by the Ministry of Food and Drug Safety (MFDS). This type of disclosure regarding significant business developments, such as clinical trial milestones, is classified as a general regulatory announcement under the RNS category, as it does not fit into specific categories like financial reports, dividends, or M&A.
2023-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (정기주주총회결과). It details the outcomes of voting on agenda items such as financial statement approval, director appointments, and remuneration limits. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-03-29 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, grant date, and the purpose of the grant to employees. Since this document relates to the issuance of stock options (a form of capital/equity change) and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is classified as a Regulatory Filing (RNS) as it is a standard corporate disclosure required by the exchange.
2023-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by TiumBio. It contains the auditor's opinion (적정/Unqualified), financial statements (consolidated and separate), and key financial metrics such as assets, liabilities, and operating losses. While it provides financial data, it is a regulatory disclosure of the audit results rather than the full 10-K annual report itself. In the context of Korean regulatory filings (DART/KIND), this specific disclosure format is categorized as an Audit Report/Information filing. FY 2022
2023-03-21 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2022 (Jan 1, 2022 - Dec 31, 2022) for TiumBio Co., Ltd. It contains detailed sections on company overview, history, capital changes, governance, and business operations (including R&D pipelines). This structure and content align perfectly with the definition of an Annual Report (10-K) in the provided schema, as it is the official yearly report covering company activity and financial performance. FY 2022
2023-03-21 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.